BACKGROUND & AIMS: The gradual accumulation of hepatic fibrosis in chronic liver disease results in clinical complications. The rate of hepatic fibrosis score progression (RFSP) in predicting clinical outcomes was assessed by extending the 4-year Hepatitis C Antiviral Long-term Treatment Against Cirrhosis (HALT-C) Trial to include preenrollment liver biopsies. METHODS: The RFSP was calculated from the linear regression slope of Ishak fibrosis score vs time in 457 patients with liver biopsies (≥10-mm length) prior to the HALT-C Trial (575 biopsies) plus 1101 on-study biopsies (total 1676 biopsies). Individual slopes were calculated if duration from first to last biopsy was > 4 years. RESULTS: The RFSP as average fibrosis score vs average time in intervals (0-3 and >3 years prestudy, screening, month 24 and 48 on-study) in 455 patients in cohorts of baseline Ishak score ranged from 0.005 with Ishak score 2 to 0.124 with Ishak 6. The RFSP in individual patients (-0.35 to +0.97 Ishak units/year) had a mean of 0.12 ± 0.23 in 344 patients with prestudy and on-study biopsies (group A) and only 0.17 ± 0.22 in 169 with prestudy and screening biopsies (group B). Group A patients with RFSP slope ≥ 0.2 (95 patients, 27.6%) had higher 7-year cumulative rates of non-hepatocellular carcinoma outcomes (46% vs 8%, respectively) and with a hepatocellular carcinoma (10% vs 3%, respectively) than RFSP slope < 02 (249 patients, 72.4%) (P < .0001). RFSP and screening Ishak score correlated independently (P <.0001) with clinical outcomes in multivariate analysis. CONCLUSIONS: Rapid RFSP (>0.2), which occurred in 26.7% of HALT-C Trial patients, correlated strongly with clinical outcomes.
RCT Entities:
BACKGROUND & AIMS: The gradual accumulation of hepatic fibrosis in chronic liver disease results in clinical complications. The rate of hepatic fibrosis score progression (RFSP) in predicting clinical outcomes was assessed by extending the 4-year Hepatitis C Antiviral Long-term Treatment Against Cirrhosis (HALT-C) Trial to include preenrollment liver biopsies. METHODS: The RFSP was calculated from the linear regression slope of Ishak fibrosis score vs time in 457 patients with liver biopsies (≥10-mm length) prior to the HALT-C Trial (575 biopsies) plus 1101 on-study biopsies (total 1676 biopsies). Individual slopes were calculated if duration from first to last biopsy was > 4 years. RESULTS: The RFSP as average fibrosis score vs average time in intervals (0-3 and >3 years prestudy, screening, month 24 and 48 on-study) in 455 patients in cohorts of baseline Ishak score ranged from 0.005 with Ishak score 2 to 0.124 with Ishak 6. The RFSP in individual patients (-0.35 to +0.97 Ishak units/year) had a mean of 0.12 ± 0.23 in 344 patients with prestudy and on-study biopsies (group A) and only 0.17 ± 0.22 in 169 with prestudy and screening biopsies (group B). Group A patients with RFSP slope ≥ 0.2 (95 patients, 27.6%) had higher 7-year cumulative rates of non-hepatocellular carcinoma outcomes (46% vs 8%, respectively) and with a hepatocellular carcinoma (10% vs 3%, respectively) than RFSP slope < 02 (249 patients, 72.4%) (P < .0001). RFSP and screening Ishak score correlated independently (P <.0001) with clinical outcomes in multivariate analysis. CONCLUSIONS: Rapid RFSP (>0.2), which occurred in 26.7% of HALT-C Trial patients, correlated strongly with clinical outcomes.
Authors: Lucy E Wilson; Michael Torbenson; Jacquie Astemborski; Hawazin Faruki; Charles Spoler; Rudra Rai; Shruti Mehta; Gregory D Kirk; Kenrad Nelson; Nezam Afdhal; David L Thomas Journal: Hepatology Date: 2006-04 Impact factor: 17.425
Authors: Adam Lawson; Simone Hagan; Kara Rye; Nader Taguri; Sonia Ratib; Abed M Zaitoun; Keith R Neal; Stephen D Ryder; William L Irving Journal: J Hepatol Date: 2007-03-07 Impact factor: 25.083
Authors: Robert A Levine; Schuyler O Sanderson; Robert Ploutz-Snyder; Frank Murray; Elaine Kay; John Hegarty; Niamh Nolan; Dermot Kelleher; George McDonald; J Conor O'Keane; John Crowe Journal: Clin Gastroenterol Hepatol Date: 2006-08-08 Impact factor: 11.382
Authors: Adrian M Di Bisceglie; Mitchell L Shiffman; Gregory T Everson; Karen L Lindsay; James E Everhart; Elizabeth C Wright; William M Lee; Anna S Lok; Herbert L Bonkovsky; Timothy R Morgan; Marc G Ghany; Chihiro Morishima; Kristin K Snow; Jules L Dienstag Journal: N Engl J Med Date: 2008-12-04 Impact factor: 91.245
Authors: Mengjun Wang; Karthik Devarajan; Amit G Singal; Jorge A Marrero; Jianliang Dai; Ziding Feng; Jo Ann S Rinaudo; Sudhir Srivastava; Alison Evans; Hie-Won Hann; Yinzhi Lai; Hushan Yang; Timothy M Block; Anand Mehta Journal: Cancer Prev Res (Phila) Date: 2015-12-28
Authors: Parvathi Mohan; Bruce A Barton; Michael R Narkewicz; Jean P Molleston; Regino P Gonzalez-Peralta; Philip Rosenthal; Karen F Murray; Barbara Haber; Kathleen B Schwarz; Zachary D Goodman Journal: Hepatology Date: 2013-09-30 Impact factor: 17.425
Authors: Martin L Decaris; Claire L Emson; Kelvin Li; Michelle Gatmaitan; Flora Luo; Jerome Cattin; Corelle Nakamura; William E Holmes; Thomas E Angel; Marion G Peters; Scott M Turner; Marc K Hellerstein Journal: PLoS One Date: 2015-04-24 Impact factor: 3.240